The president told a White House news conference on Friday that the country will have at least 100 million doses of vaccine by the end of the year, or "likely much more than that", Xinhua reported.
After coronavirus, a large number of people in China are now being found positive for a bacterial infection in one of its Northeast regions. The spread of the infection is taking place after leak in the biopharmaceutical plant which produces Bacterial Vaccine. Reports say that so far close to 3,300 people out of the popullation of 30 lakh have already been infected by a disease called Brucellosis.
Nearly 30 coronavirus vaccine candidates in pre-clinical and clinical stages are under development by the pharmaceutical industry and academia in India, Union Health Minister, Dr. Harsh Vardhan told the Parliament on Friday.
As clinical trials of different COVID-19 vaccines are in various phases across the globe, an AIIMS (All India Institute of Medical Sciences) doctor said that if everything goes as planned.
Coronavirus vaccine update: US-based biotech firm Moderna is actively preparing for a potential commercial launch of coronavirus vaccine mRNA-1273, the company's CEO has said.
Dr Sanjay Rai, head of the Community Medicine Department at AIIMS-Delhi on Friday said that there is a possibility of normalcy returning to India by mid-next year, with or without a coronavirus vaccin
China has approved the trials of its first nasal spray vaccine against coronavirus. The only nasal spray vaccine is expected to start phase I clinical trials in November, and it is recruiting 100 volunteers.
AstraZeneca CEO Pascal Soriot on Wednesday expressed hopes that a vaccine against the novel coronavirus developed by the pharmaceutical company would be ready by the end of 2020 or early 2021, despite having to pause clinical trials.
Serum Institute of India has put trials of AstraZeneca’s COVID-19 vaccine candidate on hold until the British drugmaker restarts the trials, Serum said on Thursday.
The suspension of a huge COVID-19 vaccine study over an illness in a single participant shows there will be “no compromises” on safety in the race to develop the shot, the chief of the National Institutes of Health told Congress on Wednesday.
The Serum Institute of India (SII), which is conducting Oxford-AstraZeneca coronavirus vaccine phase 2 and 3 trials in India, has received a show-cause notice from the central drug regulator for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford vaccine candidate in other countries and also for not submitting casualty analysis of the "reported serious adverse events".
Shares of AstraZeneca Pharma, closed over 3 per cent lower on Wednesday after its COVID-19 vaccine study was paused following a participant's unexplained illness.
The Russian Health Ministry said on Wednesday that the developers of the anti-coronavirus vaccine Sputnik V are ready to make it available for people all over the world.
The Serum Institute of India (SII), which is conducting Oxford-AstraZeneca coronavirus vaccine phase 2-3 trials in India, has said that the Indian trials of the vaccine are continuing and they can't comment on the UK trials which have been paused after a patient developed unexplained illness.
"We hope to have good news about vaccine for COVID-19, once vaccines are available it will be available to all countries on equitable basis," said Director-General of WHO Tedros Adhanom Ghebreyesus during 73rd session of WHO Regional Committee for So
The spokesperson termed the pause as "a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials."
Pharmaceutical company AstraZeneca on Tuesday "voluntarily paused" a randomised clinical trial of its coronavirus vaccine. The company is developing the drug alongside the University of Oxford, a frontrunner in the global race for a COVID-19 vaccine.
NITI Aayog member Dr. VK Paul during the Health Ministry briefing said that the vaccine developed by Russia has been under consideration of the country.
Coronavirus is raging like wildfire across the country, making India the second worst-hit country after the United States. But there is a bright spot amid this mayhem -- India's first indigenous coronavirus vaccine, Covaxin developed by Hyderabad-based Bharat Biotech, is likely to be launched in early 2021.
The second batch of Sputnik V vaccine for public use is already being produced in the Gamaleya Centre, Alexander Gintsburg, the director of the research institute said in an interview on Tuesday. Gintsburg stated that each batch of the vaccine must first gain approval from federal healthcare authorities before being distributed to the population.
Top News
Latest News
